摘要:
A metered-dose inhaler includes at least one vessel and an actuator for receiving the at least one vessel. The at least one vessel includes a first reservoir containing a first formulation and a second reservoir containing a second formulation. The metered-dose inhaler is actuable when the at least one vessel is received by the actuator. The metered-dose inhaler is configured to simultaneously deliver a first metered dose of the first formulation and a second metered dose of the second formulation upon actuation.
摘要:
A powder for use in a dry powder inhaler comprises: i) a fraction of fine particle size constituted by a mixture of physiologically acceptable excipient and an additive; ii) a fraction of coarse particles; and iii) at least one active ingredient. The powder is suitable for efficacious delivery of active ingredients into the low respiratory tract of patients suffering from pulmonary diseases such as asthma. In particular, the invention provides a formulation to be administered as dry powder for inhalation which is freely flowable, can be produced in a simple way, is physically and chemically stable and capable of delivering accurate doses and/or high fine particle fraction of low strength active ingredients by using a high- or medium resistance device.
摘要:
A device for delivering metered aerosols g an active ingredient in solution in a propellant consisting of a hydrofluoroalkane (HFA), selected from 1,1,1,2-tetrafluoroethane (HFA 134a), 1,1,1,2,3,3,3-heptafluoropropane (HFA 227) or mixtures thereof, a co-solvent such as ethanol and optionally a low-volatility component preferably selected from glycerol, propylene glycol polyethylene glycol, oleic acid and isopropyl myristate, said device comprising a flat body with a seat for housing the can, an inhalation mouthpiece and an expansion chamber shaped to create a vortex flow of the aerosol particles expelled by the actuator, wherein the actuator orifice diameter is in the range between 0.30 and 0.50 mm.
摘要:
In a solution composition for use in an aerosol inhaler which comprises an active material, a propellant containing a hydrofluoroalkane, a cosolvent and optionally a low volatility compound the use of a mixture of HFA 134a and HFA 227 allows to modulate the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler to target specific regions of the respiratory tract. Moreover the fine particle dose (FPD) of the active ingredient in the composition increases by reducing the metering chamber volume.
摘要:
Compositions which contain an active ingredient, a propellant containing a hydrofluoroalkane (HFA), a co-solvent, and a low-volatility component are useful for administering the active ingredient via an aerosol.
摘要:
A formulation for an inhaler device comprises carrier particles having a diameter of at least 50 μm and a mass median diameter of at least 175 μm; active particles; and additive material to which is able to promote release of the active particles from the carrier particles on actuation of the inhaler device. The formulation has excellent flowability even at relatively high fine particle contents.
摘要:
The invention relates to pressurized metered dose inhalers (MDIs) in which all or part of the internal surface is stainless steel, anodized aluminum, or lined with an inert organic coating and which contain a formulation which comprises ipratropium bromide.
摘要:
A method for delivering two or more active drug substances to the lungs by inhalation from a single pressurized metered dose inhaler product, said inhaler containing a HFA/cosolvent based solution formulation wherein all the active drug substances are fully dissolved in the formulation.
摘要:
The invention discloses formulations for administration with pressurized metered dose inhalers containing as active ingredient esters of 3,17-dihydroxy oestratriene derivatives, in solution in a hydrofluorocarbon propellant, optionally one or more co-solvents, and their use for the treatment of postmenopausal symptoms as well as of menstrual migraine headaches.
摘要:
The present invention relates to a pharmaceutical formulation for use in the administration of 2(1H)-quinolinone derivatives long-acting β2-agonists by inhalation. In particular this invention relates to a chemically stable highly efficient TA 2005 HFA solution formulation to be administered by pressurised metered dose inhalers (pMDIs) characterized by a deep lung penetration. The invention also relates to methods for the preparation of said formulation and to its use in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).